Last updated: March 28, 2026
What are the Criteria for Patentability of Biopharmaceuticals in the Philippines?
Biopharmaceutical inventions must meet three main criteria under the Philippines' Intellectual Property Code (Republic Act No. 8293):
- Novelty
- Inventive Step
- Industrial Applicability
Novelty requires that the invention is not part of the prior art anywhere globally before the filing date. No identical or similar inventions must have been disclosed publicly, including publications, patents, or clinical data.
Inventive step demands that the invention is not obvious to a person skilled in the field. This considers existing knowledge and prior arts, including published scientific papers and earlier patent filings.
Industrial applicability confirms that the invention can be used or produced in any industry, including the pharmaceutical or healthcare sector.
The Philippines adheres closely to international standards, referencing the Patent Cooperation Treaty (PCT) and agreements with the World Trade Organization (WTO). The examination process emphasizes strict novelty and inventive step criteria for biopharmaceuticals.
What Are Key Enforceability Considerations for Biopharmaceutical Patents?
Enforceability depends on comprehensive patent drafting and adherence to legal procedures:
-
Proper Disclosure: The patent must fully disclose the invention, including descriptions, best modes, and claims, sufficient for others skilled in the art to replicate the invention (utility disclosure requirement).
-
Maintenance and Renewal: Patents are valid for 20 years from filing, provided renewal fees are paid annually starting on the third year. Non-payment leads to expiration.
-
Third-Party Challenges: Third parties can file post-grant opposition within 12 months of patent grant or initiate patent infringement suits. The scope of the patent claims critically determines enforceability.
-
Legal Validity: Courts or the Intellectual Property Office (IPO) can declare the patent invalid if it fails to meet legal requirements, such as lacking novelty or inventive step, or if it was obtained through fraud or misrepresentation.
-
Patent Term Restoration: The Philippines does not have a system for patent term extensions or adjustments based on regulatory delays, unlike some jurisdictions.
How Does Claim Scope Impact Patentability and Enforcement?
The scope of claims defines the protection conferred by the patent. For biopharmaceuticals, claim drafting must balance broad protection with legal certainty and compliance:
-
Product Claims: Cover specific chemical entities, genetic sequences, or biological formulations. Broad claims may include a genus of compounds; narrow claims specify a particular molecule or method.
-
Method Claims: Encompass specific processes for manufacturing or using the biopharmaceutical. These are often easier to enforce but may have limited scope.
-
Use Claims: Cover specific therapeutic indications or applications, often used in combination with product claims to extend protection.
-
Markush Grouping: Commonly used for claiming a family of chemical compounds, but the description must clearly define the invention to prevent objections for indefiniteness.
-
Clarity and Support: Claims must be clear, definite, and supported by the description. Ambiguous or overly broad claims risk rejection or invalidation.
-
Claim Drafting Strategies: Focus on multiple dependent claims to cover various embodiments, and include narrow claims to defend against prior art challenges.
Limitations on Claims: The Philippines excludes from patentability any inventions that contravene public order or morality, including certain biotechnological inventions involving human parts or genetic resources obtained without proper consent.
Policy and Office Practice Insights
The IPO Philippines has adopted guidelines aligned with international standards, emphasizing strict examination for biopharmaceutical patent applications. They apply rigorous scrutiny to novelty and inventive step, especially regarding biological and genetic inventions.
Patent applications involving naturally occurring substances or genetic sequences must demonstrate inventive modification or specific utility, as naturally occurring substances are generally not patentable unless markedly modified.
The office also limits the scope of claims related to methods of treatment, considering them as second uses, and emphasizes the importance of detailed descriptions to support claim scope.
Summary Table
| Aspect |
Details |
Sources & References |
| Patentability criteria |
Novelty, inventive step, industrial application |
RA 8293, Sections 22-24 |
| Term |
20 years from filing |
RA 8293, Section 73 |
| Examination |
Strict on novelty/inventive step |
IPO Philippines Guidelines |
| Claim scope |
Broad product, method, use claims |
Manual for Patent Drafting |
| Patent validity challenges |
Post-grant opposition, invalidation |
RA 8293, Section 57 |
| Limitations |
No patent on inventions against public order/morality |
RA 8293, Section 24 |
Key Takeaways
- Patentability hinges on strict novelty and inventive step, especially for naturally derived biopharmaceuticals.
- Proper disclosure, claim clarity, and claim breadth are critical for enforceability.
- The Philippines has a 20-year patent term, with renewal obligations and no patent term extensions.
- Enforcement depends on well-drafted claims, registered status, and the ability to defend against invalidity claims.
- The scope of claims significantly impacts both the scope of protection and vulnerability to prior art challenges.
FAQs
Q1: Can naturally occurring biological substances be patented in the Philippines?
Answer: Generally, no. Naturally occurring substances are excluded unless a markedly inventive modification is demonstrated.
Q2: How does the Philippines define inventive step?
Answer: It considers whether the invention would be obvious to a person skilled in the art based on prior knowledge and publications at the time of filing.
Q3: Are method claims for biopharmaceuticals enforceable in the Philippines?
Answer: Yes, but they are often narrower and require clear descriptions to withstand validity assessments.
Q4: What is the process for challenging a biopharmaceutical patent post-grant?
Answer: A third-party can file a formal opposition within 12 months of grant. Courts or the IPO can later invalidate the patent on legal grounds.
Q5: Does the Philippines allow patent term extensions for regulatory delays?
Answer: No, the Philippines does not permit patent term extensions similar to some jurisdictions like the U.S. or Europe.
References
- Philippine Patent Law, Republic Act No. 8293. (1997). Retrieved from https://www.ipophil.gov.ph/legal-policies/
- IPO Philippines Examination Guidelines. (2022). Available from the Intellectual Property Office official website.
- World Intellectual Property Organization. (2020). Patentability of Biological Inventions. WIPO/PUB/2020/2.
- World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
